4//SEC Filing
Warmuth Markus 4
Accession 0000899243-21-025976
CIK 0001826457other
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 5:00 PM ET
Size
8.6 KB
Accession
0000899243-21-025976
Insider Transaction Report
Form 4
Warmuth Markus
DirectorPresident & CEO
Transactions
- Award
Stock Option (Right to Buy)
2021-06-23+141,623→ 141,623 totalExercise: $19.00Exp: 2031-06-22→ Common Stock (141,623 underlying) - Award
Stock Option (Right to Buy)
2021-04-12+538,517→ 538,517 totalExercise: $6.14Exp: 2031-04-12→ Common Stock (538,517 underlying)
Footnotes (4)
- [F1]On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
- [F2]This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
- [F3]25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
- [F4]25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Documents
Issuer
Monte Rosa Therapeutics, Inc.
CIK 0001826457
Entity typeother
Related Parties
1- filerCIK 0001855643
Filing Metadata
- Form type
- 4
- Filed
- Jun 24, 8:00 PM ET
- Accepted
- Jun 25, 5:00 PM ET
- Size
- 8.6 KB